Negative regulation of the NF-kB transcription factor is essential for tissue homeostasis in response to stress and inflammation. NF-kB activity is regulated by a variety of biochemical mechanisms including phosphorylation, acetylation, and ubiquitination. In this study, we provide the first experimental evidence that NF-kB is regulated by SUMOylation, where the RelA subunit of NF-kB is SUMOylated by PIAS3, a member of the PIAS (protein inhibitor of activated STAT) protein family with E3 SUMO ligase activity. PIAS3-mediated NF-kB repression was compromised by either RelA mutant resistant to SUMOylation or PIAS3 mutant defective in SUMOylation. PIAS3-mediated SUMOylation of endogenous RelA was induced by NF-kB activation thus forming a negative regulatory loop. The SUMOylation of endogenous RelA was enhanced in IkBa null as compared with wild type fibroblasts. The RelA SUMOylation was induced by TNFa but not leptomycin B mediated RelA nuclear translocation. Furthermore, RelA mutants defective in DNA binding were not SUMOylated by PIAS3, suggesting that RelA DNA binding is a signal for PIAS3-mediated SUMOylation. These results support a novel negative feedback mechanism for NF-kB regulation by PIAS3-mediated RelA SUMOylation. 
Introduction
NF-kB is a transcription factor that mediates cellular response to inflammation, immune response, and stress [1] . Deregulation of NF-kB is one of the common features in many pathological disorders including inflammatory diseases and cancer. NF-kB is a dimeric protein which can be comprised of a variety of combinations of Rel family DNA binding proteins including RelA (p65), RelB, c-Rel, p50, and p52. A heterodimer of RelA and p50 is the most common combination in the canonical NFkB signaling pathway. In unstimulated cells, NF-kB is held in check by the inhibitor of NF-kB (IkBa) which sequesters NF-kB in the cytoplasm and prevents NF-kB DNA binding. Upon stimulation, IkBa is phosphorylated by IkB kinases, leading to its degradation. The degradation of IkBa allows the free NF-kB to translocate to the nucleus where it functions as a transcription factor to induce the expression of proinflammatory cytokines, chemokines, and factors for cell proliferation and survival [2] .
Aberrant activation of NF-kB is detrimental to the host and may lead to a variety of inflammation related diseases like cancer, psoriasis and arthritis. Thus, as in many other signal transduction pathways, there are multiple feedback mechanisms to balance the activity of NF-kB. A well established mechanism is NF-kB dependent induction of IkBa which disrupts NF-kB DNA binding and shuttles nuclear NF-kB back to cytoplasm, thus forming a negative regulation loop [3, 4, 5] . A20 is another NF-kB induced gene that inhibits NF-kB activity by degrading receptor interacting protein (RIP), an essential mediator for the activation of the TNF receptor-associated signaling complex in the cytoplasm [6] . In addition to negative regulation by NF-kB inducible genes, NF-kB is negatively regulated by CYLD, a deubiquitinase that represses the activation of the IKK complex by removing K63-linked ubiquitin chains from TRAFs and NEMO [7, 8, 9] .
In addition to protein ubiquitination, growing evidence suggests that several proteins in the NF-kB pathway are regulated by SUMOylation [10] . SUMOylation is a posttranslational modification involving covalent conjugation of small ubiquitin-like modifier proteins (SUMO) to target proteins. In contrast to protein ubiquitination, which generally tags proteins for proteasome-mediated degradation, SUMOylation modulates protein localization, protein/protein interaction, transcriptional regulation, as well as protein stabilization. SUMOylation of IkBa inhibits NF-kB activation by blocking IkBa ubiquitination and degradation [11] . In response to genotoxic stress but not inflammatory challenge, NF-kB is activated by PIASy-mediated NEMO SUMOylation [12] .
Mammalian PIAS has four family members including PIAS1, PIAS2 (PIASx), PIAS3, and PIASy [13] . PIAS proteins have four conserved structural domains and motifs: a SAP domain for chromatin binding, PINIT motif for localization, SP-RING domain for E3-SUMO ligation, and a SUMO-interacting motif for SUMO binding. While PIASy-mediated NEMO SUMOylation contributes to NF-kB activation [12] , PIAS1 and PIAS3 inhibit NF-kB activity by direct binding to the RelA subunit of NF-kB [14, 15] . PIAS1 binds to the C-terminal transactivation domain of RelA and blocks RelA binding to DNA in vitro and in vivo [14] . PIAS3 binds to the N-terminal DNA binding domain of RelA and interferes with RelA binding to the CBP coactivator [15] . In our previous studies, we also found that PIASy represses NF-kB activity in mouse keratinocytes and represses the expression of CCL20 chemokine in response to TNFa and/or IL-17A [16] . Although SUMO modification has been suggested as a mechanism for transcriptional repression conserved from yeast to human [17] , RelA SUMOylation and its role in transcriptional regulation have not been defined.
In this study, we provide in vitro (cell free) and in vivo evidence that RelA is SUMOylated. RelA is predominantly SUMOylated by PIAS3, among PIAS family proteins. PIAS3-mediated NF-kB repression is compromised by either RelA mutant resistant to SUMOylation or PIAS3 mutant defective in SUMOylation. The SUMOylation of endogenous RelA by PIAS3 is induced by NFkB activation. Furthermore, PIAS3-mediated RelA SUMOylation was dependent on RelA DNA binding. These data suggest PIAS3-mediated RelA SUMOylation as a novel negative regulatory mechanism for NF-kB regulation.
Materials and Methods

Plasmids
Flag-tagged RelA/p65 was constructed by cloning the RelA/ p65 coding sequence from HA-tagged RelA (kindly provided by S. Ghosh, Yale University) into pCMVTag2B vector (Stratagene). V5-tagged RelA was constructed by cloning RelA coding sequence from Flag-tagged RelA vector into pCDNA-v5 vector (Invitrogen). RelA mutants (121/122K.R, 37K.R, 39E.I, 36Y.A) and catalytically dead PIAS3 mutant (299C.S) were generated by targeted mutagenesis (Stratagene). His-tagged RelA and PIAS3 were cloned into pET-24a expression vector for the production of PIAS3 and RelA recombinant protein in BL-21 E. coli cells. Flagtagged Pias1and PIAS3 cDNA were kindly provided by Shaiu Ke, UCLA. His-tagged SUMO3 and constitutively active IKK2 were kindly provided by Paul Fraser [18] and Anjana Rao [19] , respectively.
Cell Culture and Transfection
Human embryonic kidney 293T (HEK293T) cells (Invitrogen), mouse 3T3 fibroblasts [20] , IkBa null fibroblasts and wild type fibroblasts [3, 4, 5] were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Cells were transfected in serum free OptiMEM medium (Invitrogen) at 90% confluence using Transfectin (Bio-Rad) according to the manufacturer's instructions.
Expression and Purification of Recombinant Bacterial Proteins
BL-21 cells containing the 66his-and 66his-Flag expression vectors noted above were grown to log phase in 300 ml Luria broth and induced with 1 mM IPTG (Fisher) for 1 hour. The cells were centrifuged at 5000 rpm for 5 mins at 4uC. The pellet was diluted in nickel lysis buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 20 mM imidazole, pH 8.0), treated with lysozyme (1 mg/ml) for 20 minutes on ice, and sonicated. The crude lysate was clarified by centrifugation at 10,000 rpm for 20 min. The lyaste was incubated with 1 mL of Ni-NTA agarose slurry (Invitrogen) in nickel lysis buffer for 1 hr at 4uC. The beads were washed three times with 6 ml nickel wash buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 60 mM imidazole, pH 8.0), and eluted in 500 mL fractions using the nickel elution buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 250 mM imidazole, pH 8.0). The eluants were dialyzed against DNAB buffer (50 mM NaCl, 20 mM Tris [pH7.2]; 4% glycerol; 0.1% Triton-100; 1 mM EDTA). The purity and concentration of purified proteins were verified by Coomassie stain and immunoblotting.
In vivo SUMOylation Assay
Murine 3T3 cells were transfected with His6-tagged SUMO vector, V5-tagged RelA vector, and Flag-tagged PIAS vectors, and other vectors as indicated. 24 hrs after transfection, cells were washed twice with PBS and harvested in 1 ml of PBS. Fifty percent of cells collected were lysed in RIPA buffer and used for direct immunoblotting. The remainder was lysed in denaturing lysis buffer (6 ml of 6 M guanidinium-HCl, 0.1 M Na2HPO4/ NaH2PO4, 0.01 M Tris/HCl, pH 8.0, 5 mM, imidazole and 10 mM beta-mercaptoethanol). 50 ml of Ni 2+ -NTA-agarose beads (Qiagen) were then added and lysates were rotated at room temperature (RT) for 4 h. The beads were washed for 5 min between each step at room temperature with each of the following buffers, successively: Buffer A (6 M guanidinium-HCl, 0.1 M Na2HPO4/NaH2PO4, 0. 
In vitro SUMOylation Assay
His-tagged RelA, RelA 122R mutant, and PIAS3 proteins were produced in BL-21 E. coli transformed with the corresponding pET-24a expression vectors by IPTG induction for 1 hour at room temperature. The His-tagged proteins were purified by Ni-NTA affinity purification in lysis buffer (50 mM NaHPO4 pH8, 300 mM NaCl, 10 mM imidazole). The eluted proteins were dialyzed against binding buffer (50 mM Tris [pH7.2]; 4% glycerol; 0.1% Triton-100; 1 mM EDTA; 50 mM NaCl). The in vitro SUMOylation assay was performed in 40 ml of reaction buffer (20 mM HEPES [pH 7.4], 50 mM MgCl2, 20 mM ATP) with 0.1 mg of SAE1/SAE2 (Boston Biochem), 0.1 mg of Ubc9 (Boston Biochem), 6 ug of SUMO3, 15 ng of RelA, and 0.2 mg of PIAS3 at 37C for one hour. The reaction was terminated by 56 SDS sample buffer. The SUMOylated products were visualized by immunoblotting with anti-RelA antibody.
Luciferase Assay
Mouse 3T3 cells were plated in 24 well plates and transfected with NF-kB reporter, and b-galactosidase reporter vectors. 24 hrs post-transfection, cells were lysed in luciferase assay buffer (0.1 M NaPO4 [pH 8.0], 4 mM ATP, 1 mM pyrophosphate, 1 mM MgCl, 20 mM DTT) supplemented with 0.2% Triton-100. Cleared supernatants were used for luciferase measurement. The b-galactosidase activity was measured by Tropix galacto-light beta-galactosidase assay (Applied Biosystems) for data normalization. The relative NF-kB luciferase activity was calculated by dividing the signal of NF-kB reporter by that of b-galactosidase.
His-SUMO3 Lentivirus
His-SUMO3 [18] was cloned into XhoI/EcoRI sites of pSL35 lentiviral vector [21] . His-SUMO3 lentiviruses were generated using the four-plasmid system by cotransfection of 293T cells with pSL3, which expresses the vesicular stomatitis virus G envelope protein; pSL4, which expresses the HIV-1 gag/pol genes; pSL5, which expresses the rev gene; and pSL35 containing His-SUMO3. Lentivruses were harvested at 48 and 72 h after the transfection and concentrated by ultracentrifugation at 500,0006g for 90 min. The recombinant virus titer was determined for use of minimal viral particles to achieve $90% infection of IkBa null fibroblasts and wild type fibroblasts.
DNA Affinity Immunoblot
RelA DNA binding activity was measured by DNA affinity immunoblotting, a sensitive in vitro technique for measurement of endogenous DNA binding proteins [22] . A 200 mg aliquot of nuclear extract was mixed with biotinylated NF-kappaB consensus binding sequence, biotin-CATAAGTCATGAGTTGAGGG-GACTTTCCCAGGC in 16 DNA binding buffer [20 mM Tris (pH 7.2), 1 mM EDTA, and 0.06% Triton X-100 supplemented with 5 mM DTT, and 10 mg salmon sperm DNA), with a final NaCl level equal to 250 mM and glycerol level equal to 4%] in cold room for 30 minutes. The DNA bound proteins were captured by streptavidin magnasphere paramagnetic particles (Promega) and analyzed by immunoblotting.
Results
RelA SUMOylation by PIAS3
To determine whether RelA is SUMOylated by PIAS proteins, we evaluated in vivo RelA SUMOylation in murine 3T3 cells transiently transfected with V5-tagged RelA, Flagtagged PIAS proteins, and His-tagged SUMO3. Analysis of nickel-affinity purified RelA from the cell lysate revealed several slowly migrating forms of RelA ( Figure 1A ). As the slowly migrating forms of RelA were dependent on co-transfection of his-tagged SUMO3 ( Figure S1 ), they represent SUMOylated RelA species with one or more SUMO3 molecules. Although RelA SUMOylation by PIAS1 and PIASy was detectable, PIAS3 showed the most potent effect on RelA SUMOylation. PIAS3-dependent RelA SUMOylation was also detected in other cell types such as HEK293 and H1299 cells ( Figure S2 ). To test whether endogenous RelA is SUMOylated by PIAS3, we evaluated RelA SUMOylation by in vivo SUMOylation assay in 3T3 cells transiently transfected with Flag-tagged PIAS and Histagged SUMO3. The SUMOylation of endogenous RelA by either PIAS1 or PIASy was barely detectable ( Figure 1B ). The endogenous RelA was SUMOylated by PIAS3 only after NF-kB activation by treatment of cells with TNFa ( Figure 1B) . Taken together, these data provide evidence that RelA is SUMOylated and that RelA SUMOylation is mediated by PIAS3.
Lysine 37, 121/122 are the Major SUMOylation Sites in RelA
Protein SUMOylation generally targets lysine residues in a yKXE consensus sequence [23] , where y is a hydrophobic amino acid residue, X represents any residue, E is an acidic residue, and K is a lysine residue to which SUMO moiety is covalently bound. There is no perfectly matched yKXE consensus sequence in RelA protein. However, several nearly matched yKXE consensus sequences in RelA protein are 37K(YKCE), 121/122K (VKKRD), and 222K (QKED). In vivo SUMOylation analysis of these RelA mutants revealed that PIAS3-mediated RelA SUMOylation was compromised by RelA mutations from lysine to arginine at 37 and 121/122 respectively (Figure 2A ). PIAS3-mediated RelA SUMOylation was virtually abolished by compound mutation of 37K and 121/122K, indicating that lysine residues at 37 and 121/122 are involved in PIAS3-mediated RelA SUMOylation. To further define the role of PIAS3 in RelA SUMOylation, we conducted in vitro SUMOylation assays with purified RelA and PIAS3 proteins. As expected, RelA SUMOylation was abolished in the absence of either E1 enzyme (SAE1) or E2 enzyme (Ubc9) in the in vitro SUMOylation reaction. Consistent with the in vivo SUMOylation assays and RelA mutational analysis, RelA SUMOylation in vitro was enhanced by PIAS3 ( Figure 2B ) and RelA SUMOylation was compromised by 121/122 K.R mutation.
RelA SUMOylation Dependent NF-kB Repression
Protein SUMOylation has been associated with a number of cellular activities including transcriptional repression by altering protein interactions [24] . To test the effects of PIAS3-mediated RelA SUMOylation, NF-kB luciferase activity was measured in 293T cells transfected with wild type RelA and SUMO defective RelA (SD-RelA, RelA with K.R mutations at 37, 121, and 122) ( Figure 3A) . NF-kB activation by wild type RelA was significantly repressed by PIAS3 overexpression. However, PIAS3-dependent NF-kB repression was compromised in the SUMOylation defective RelA mutant. As lysine is the accept site not only for SUMOylation but also for acetylation, methylation, and ubiquitination, these modifications may potentially contribute to altered NF-kB activity of SUMO defective RelA. To further define the contribution of RelA SUMOylation to NF-kB repression, NF-kB luciferase activity was compared in 293T cells transfected with wild type PIAS3 and catalytically dead PIAS3 mutant (CD-PIAS3, PIAS3 with C.S mutation at 299) ( Figure 3B ). The catalytically dead PIAS3 mutant failed to mediate RelA SUMOylation in response to NF-kB activation by constitutively active IKK2. These results suggest PIAS3-mediated RelA SUMOylation as a mechanism of NF-kB transcriptional repression.
PIAS3 Mediated RelA SUMOylation is Induced by NF-kB Activation
Because PIAS3-mediated RelA SUMOylation was associated with NF-kB inhibition, we evaluated RelA SUMOylation as a potential mechanism for NF-kB negative regulation after activation by either TNFa treatment or co-transfection of constitutively active IKK2. Similar to TNFa treatment, the SUMOylation of endogenous RelA was induced by IKK2 cotransfection ( Figure 4A ). Analysis of NF-kB activity in the corresponding cells confirmed NF-kB activation by either TNFa treatment or IKK2 co-transfection ( Figure 4B ). In addition, the NF-kB activation by TNFa or IKK2 was repressed by PIAS3. This suggests that NF-kB activation is required for PIAS3-mediated RelA SUMOylation. Because NF-kB activation is repressed by PIAS3, RelA SUMOylation by PIAS3 is likely a mechanism for NF-kB negative regulation.
To further define the role of NF-kB activation in RelA SUMOylation, we examined the kinetics of PIAS3-mediated RelA SUMOylation in response to TNFa treatment. PIAS3-mediated RelA SUMOylation was observed 150 minutes after TNFa treatment and increased with time after TNFa treatment ( Figure 4C ). These results are consistent with RelA SUMOylation by PIAS3 as a negative regulatory mechanism for NF-kB.
DNA Binding Dependent RelA SUMOylation by PIAS3
The central mechanism of NF-kB regulation is through the NFkB negative regulator, IkBa, which sequesters NF-kB in the cytoplasm and dissociates NF-kB from DNA in the nucleus [2] . To further define the role of PIAS3-mediated RelA SUMOylation as a negative regulator of activated NF-kB in the nucleus, we evaluated RelA SUMOylation in cells with IkBa null background. To overcome low transfection frequency of IkBa null cells compared to wild type cells, we established cell lines with stable expression of His-tagged SUMO3. In the absence of TNFa, RelA SUMOylation was barely detected in either wild type or IkBa null cell lines. RelA SUMOylation was induced in both wild type and IkBa null cell lines upon TNFa treatment. IkBa null cells showed much stronger RelA SUMOylationon than its wild type counterpart ( Figure 5A ). To test whether enhanced RelA SUMOylation in IkBa null cells is associated with increased RelA nuclear accumulation or RelA DNA binding capability, we evaluated RelA SUMOylation in wild type and IkBa null cells treated with leptomycin B to block RelA nuclear export. Upon leptomycin B treatment, RelA accumulated in the nucleus in both wild type and IkBa null cells ( Figure 5 ). However, RelA SUMOylation was detected only after TNFa treatment, not in either cell line treated with leptomycin B alone, showing that nuclear accumulation of RelA was insufficient for RelA SUMOylation.
Because dissociation of RelA DNA binding is another function of IkBa, we evaluated whether RelA DNA binding is required for PIAS3-mediated SUMOylation of RelA by using RelA mutants (39E.I and 36Y.A) defective in DNA binding [25] . The 39E.I and 36Y.A mutants, conferred defects in NF-kB activation as expected ( Figure 6A ). Consistent with previous DNA binding data [25] , the39E.I and 36Y.A mutants failed to bind NF-kB consensus DNA binding sequence whereas the DNA binding activity of 37K.R mutant was not affected ( Figure 6B ). Compared with wild type RelA and SUMOylation compromised mutant at 37K, PIAS3-mediated RelA SUMOylation was abolished by both 39E.I and 36Y.A mutants ( Figure 6B ). It is of interest to note that weak RelA SUMOylation was induced independent of PIAS3 in the 36Y.A mutant ( Figure 6C ), likely due to the generation a perfectly matched SUMO consensus site (yKXE), converting a polar amino acid to a hydrophobic amino acid. Even so, PIAS3-dependent RelA SUMOylation was abolished by the same mutation. The abolition of PIAS3-mediated RelA SUMOylation by different RelA mutants defective in DNA binding suggests that DNA bound RelA is the preferred target for SUMOylation by PIAS3.
Discussion
NF-kB is known to be tightly negatively regulated by IkBa, which dissociates NF-kB from DNA and sequesters it in the cytoplasm [3, 4, 5, 26] . In this study, we provide experimental evidence for a novel mechanism for negative regulation of NF-kB by PIAS3-mediated RelA SUMOylation. PIAS3-mediated SUMOylation of endogenous RelA was observed to increase with time after TNFa stimulation, and RelA DNA binding-defective mutants were resistant to PIAS3-mediated SUMOylation. The dependence of SUMOylated RelA upon DNA binding capability as shown by DNA binding defective mutants, and upon TNFa stimulation and not simply nuclear localization after leptomycin B treatment, suggests a biochemical mechanism for NF-kB transcriptional repression.
PIAS3 has been reported to repress NF-kB activity through interfering with RelA binding to transcriptional co-activators [15] . However, PIAS3-mediated RelA SUMOylation was not considered a factor, largely due to the lack of perfectly matched SUMO consensus motifs in the RelA protein sequence and lack of detectable SUMOylated RelA under the conditions of that study.
In our study, we demonstrate RelA SUMOylation by PIAS3 under both overexpressed and physiological conditions. While RelA could be weakly SUMOylated by other PIAS proteins like PIAS1 and PIASy, endogenous RelA was SUMOylated specifically by PIAS3, indicating PIAS3 as a primary mediator for RelA SUMOylation. Approaches to knockdown PIAS3 function by shRNA targeting of PIAS3 have been unsuccessful, so far, to address PIAS3dependence of RelA SUMOylation, in part possibly due to PIAS redundancy and shRNA efficiency. However, endogenous RelA SUMOylation specifically mediated by PIAS3 was demonstrated using the catalytically dead PIAS3 mutant.
Although protein SUMOylation is associated with many cellular activities, transcriptional repression is the primary consequence of protein SUMOylation. In fact, SUMO consensus sequence (yKXE) was identified as a synergy control motif for transcriptional repression even before being recognized as a SUMO consensus sequence [27] . The identification of RelA SUMOylation has been hampered by the lack of perfectly matched yKXE consensus sequence in RelA protein [15] . Recent global analysis of SUMOylated endogenous proteins revealed that one third of SUMO sites are not perfectly matched to yKXE consensus sequences [28] . In this study, we have identified two imperfectly matched SUMOylation sites, 37K (YKCE), 121/122K (VKKRD) in RelA protein. Compound mutation of these sites abolished PIAS3-mediated RelA SUMOylation, and compromised PIAS3-mediated NF-kB repression (Figure 2 and Figure 3) . Compromised NF-kB repression by PIAS3 mutant defective in E3 SUMO ligase activity further supported the role of PIAS3-mediated RelA SUMOylation in NF-kB repression ( Figure 3B ). These data suggest that RelA SUMOylation is a mechanism for NF-kB negative regulation, consistent with the known role of SUMOylation in transcriptional repression.
So far, the mechanism of RelA SUMOylation-mediated transcriptional repression is largely unknown. A number of transcriptional repressors and corepressors are either SUMOylated or associated with SUMOylated proteins through their SUMO interacting motif, thus enabling formation of transcription repression complexes [17, 26] . SUMOylation contributes to heterochromatin establishment and maintenance in yeast and Drosophila [29, 30] . A number of transcriptional repressors are either SUMOylated or capable of binding to the SUMO moiety through the SUMO interacting motif (SIM), including HDAC1 [31] , CtBP [32] , ZEB1 [26] and CoREST [33] . However, it has been a challenge to identify SUMOylation-dependent formation of transcription repression complexes. By sequential chromatin immunoprecipitation, Shuai's group elegantly demonstrated PIAS1-dependent recruitment of heterochromatin protein 1 and DNA methyltransferase to the Foxp3 promoter [34] . These lines of evidence suggest that PIAS3-mediated RelA SUMOylation may provide a scaffold for the recruitment of transcriptional repressors with SUMO binding motifs thus leading to transcriptional repression. In addition to SUMOylation, the RelA SUMO sites are modified by methylation by SET7/9 [35] and acetylation by p300 and PCAF [36] . Further study to understand the relationship among these modifications is needed to define the mechanism of RelA SUMOylation in NF-kB transcriptional regulation.
Like many important signaling pathways, the NF-kB pathway is exquisitely regulated by multiple negative feedback regulatory mechanisms, such as the induction of IkBa to sequester NF-kB in the cytoplasm [5] and A20 to block NEMO activation [37] . In addition to NF-kB repression by RelA SUMOylation, we also demonstrated that PIAS3-mediated RelA SUMOylation was induced by NF-kB activation ( Figure 5 ). The induction of RelA SUMOylation by NF-kB activation and the repression of NF-kB activity by RelA SUMOylation suggest that PIAS3-mediated RelA SUMOylation is a negative feedback mechanism for NF-kB regulation. This notion was further supported by the evidence from IkBa null cells, in which RelA SUMOylation was significantly enhanced, suggesting its compensatory role in NFkB negative regulation.
It remains a challenge to define the molecular pathways that lead to RelA SUMOylation in response to NF-kB activation. The evidence from RelA mutants defective in DNA binding suggests that DNA-bound RelA is the preferred target for PIAS3-mediated RelA SUMOylation. In this study, RelA mutants (39E.I and 36Y.A) defective in DNA binding [25] also abolished PIAS3-mediated SUMOylation. Coincidently, both mutations reside in the N-terminal RelA SUMO consensus motif (36YKCE39). The abolition of PIAS3-mediated RelA SUMOylation by these mutations is very unlikely due to the disruption of the SUMO consensus site. Compared with the SUMOylation of 37K.R mutant, 39E.I mutation showed more severe effect on PIAS3-mediated RelA SUMOylation. Furthermore, 36Y.A mutation that generates a perfect SUMOylation motif, also abolished PIAS3-mediated RelA SUMOylation despite its enhancement of PIAS3-independent RelA SUMOylation. The abolition of PIAS3-mediated RelA SUMOylation by these various RelA DNA binding mutants suggests that RelA DNA binding is a determining factor in PIAS3-mediated RelA SUMOylation. In vitro, RelA DNA complex can be rapidly dissociated by IkBa, which reduces the half-life of the RelA DNA complex from 45 to 3 minutes [38] . RelA binding to DNA is negatively regulated by IkBa [3] , which therefore reduces the pool of DNA-bound RelA available for SUMOylation. In the absence of IkBa negative regulation, increased DNA-bound RelA is available for SUMOylation. Thus, SUMOylation of RelA could be a mechanism to halt sustained NF-kB activation that is beyond the capacity of IkBa to control. The SUMOylation of DNA-bound RelA provides a molecular basis to form heterchromatic foci at promoters of genes regulated by NF-kB, to repress transcription, thus safeguarding against sustained transcriptional activation. Future studies will be needed to illustrate the mechanisms of RelA SUMOylation in NF-kB negative regulation in specific cell contexts, including defining NFkB downstream genes affected by SUMOylation of RelA, and the associated transcriptional repressors in complex with SUMOylated RelA. Figure S1 PIAS3 mediated RelA SUMOylation is SU-MO3 dependent. 293T cells were transfected with v5 tagged RelA, flag-tagged PIAS, and his-tagged SUMO3 as indicated. 
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